NATICK, Mass., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Michael Kauffman, Chief Executive Officer, is scheduled to present at the following conferences in February:
- Leerink Swann Global Healthcare Conference 2014 on Thursday, February 13, at 3:05 p.m. ET. The conference is being held at the Waldorf Astoria in New York.
- 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, at 2:05 p.m. ET. The conference is being held at the New York Palace Hotel in New York.
Both presentations will be webcast live and will be available under the Investors section of the Company's website at www.karyopharm.com, where they will be archived for 90 days.
In addition, Dr. Sharon Shacham, Founder, President and Chief Scientific Officer of Karyopharm and Dr. Kauffman will ring The NASDAQ Stock Market Closing Bell this afternoon to celebrate the Company's success in 2013, having reached development and corporate milestones, including the completion of an initial public offering (IPO) in November, which raised gross proceeds of approximately $125M. The event will be broadcast on the major business networks and a live webcast of The NASDAQ Closing Bell can be accessed at http://www.nasdaq.com/about/marketsitetowervideo.asx.
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by blocking XPO1, preventing the export of various proteins out of the nucleus. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.
CONTACT: Beth DelGiacco, Stern Investor Relations, Inc. email@example.com 212-362-1200